Uniphos Enterprises Limited (IN:UNIENTER)
:UNIENTER
Top Page
Uniphos Enterprises Limited
(UNIENTER)
Select Model
Select Model
Rating:46Neutral
Price Target:
₹98.00
▼(-32.58% Downside)
Action:ReiteratedDate:03/11/26
The score is held down primarily by weak operating profitability and persistently negative operating/free cash flow, despite strong recent revenue growth. A debt-free, equity-heavy balance sheet provides stability, but technicals remain bearish (below major moving averages with negative MACD) and valuation signals are not supportive given a negative P/E and low dividend yield.
Positive Factors
Debt-free balance sheet
Zero debt and a very large equity base materially lower financial risk and provide durable optionality. Over 2-6 months this balance-sheet flexibility supports funding of working capital, capex, or strategic moves without reliance on costly borrowing, improving survivability in downturns.
Negative Factors
Recurring negative operating cash flow
Consecutive years of negative operating and free cash flow signal the business is not self-funding. This recurring cash burn constrains reinvestment, heightens reliance on external funding or asset sales, and increases execution risk if the company cannot restore positive cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt and a very large equity base materially lower financial risk and provide durable optionality. Over 2-6 months this balance-sheet flexibility supports funding of working capital, capex, or strategic moves without reliance on costly borrowing, improving survivability in downturns.
Read all positive factors
Uniphos Enterprises Limited (UNIENTER) vs. iShares MSCI India ETF (INDA)
Market Cap
₹6.75B
Dividend Yield0.34%
Average Volume (3M)1.50K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees2,022
SectorBasic Materials
Sector Strength58
IndustryChemicals
Share Statistics
EPS (TTM)-0.14
Shares Outstanding69,545,845
10 Day Avg. Volume885
30 Day Avg. Volume1,505
Financial Highlights & Ratios
PEG Ratio-38.21
Price to Book (P/B)0.39
Price to Sales (P/S)9.47
P/FCF Ratio-388.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Uniphos Enterprises Limited Business Overview & Revenue Model
Company Description
Uniphos Enterprises Limited engages in trading of chemicals and other products in India. The company also invests in quoted and unquoted securities. Uniphos Enterprises Limited was incorporated in 1969 and is based in Mumbai, India. Uniphos Enterp...
How the Company Makes Money
null...
Uniphos Enterprises Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 838.64M | 1.12B | 506.48M | 14.72M | 12.22M | 8.33M |
| Gross Profit | 3.63M | 8.02M | 652.00K | 164.00K | -11.00K | 75.00K |
| EBITDA | 208.31M | 22.99M | -30.90M | -28.63M | -31.26M | -30.64M |
| Net Income | 189.89M | 2.78M | 386.14M | 392.25M | 546.04M | 244.51M |
Balance Sheet | ||||||
| Total Assets | 29.62B | 28.42B | 20.78B | 30.95B | 33.02B | 27.72B |
| Cash, Cash Equivalents and Short-Term Investments | 223.74M | 162.37M | 469.95M | 517.30M | 391.46M | 451.52M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.18B | 1.00B | 20.50M | 978.68M | 1.21B | 569.04M |
| Stockholders Equity | 28.44B | 27.42B | 20.75B | 29.98B | 31.81B | 27.15B |
Cash Flow | ||||||
| Free Cash Flow | -20.75M | -27.17M | -34.67M | -14.66M | 5.20M | -45.87M |
| Operating Cash Flow | -20.75M | -27.17M | -34.67M | -14.66M | 5.20M | -45.87M |
| Investing Cash Flow | 65.05M | 527.70M | 501.62M | 406.29M | 204.34M | -338.62M |
| Financing Cash Flow | -34.77M | -409.58M | -452.05M | -392.93M | -236.46M | 0.00 |
Uniphos Enterprises Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ₹7.12B | 9.34 | ― | 0.56% | -7.93% | 11.44% | |
62 Neutral | ₹5.96B | 19.71 | ― | 0.38% | 13.01% | 32.44% | |
62 Neutral | ₹9.34B | 17.66 | ― | 0.52% | 28.67% | 50.12% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹6.26B | 10.26 | ― | 0.81% | -4.92% | 1.29% | |
58 Neutral | ₹4.92B | -33.35 | ― | 0.28% | 5.19% | -152.09% | |
46 Neutral | ₹6.75B | -247.22 | ― | 0.34% | ― | ― |
* Basic Materials Sector Average
IN:UNIENTER
Uniphos Enterprises Limited
97.00
-57.94
-37.40%
IN:CHEMFAB
Chemfab Alkalis Ltd.
345.65
-399.77
-53.63%
IN:INDOAMIN
Indo Amines Limited
87.65
-33.03
-27.37%
IN:KOTHARIPET
Kothari Petrochemicals Ltd.
108.93
-51.64
-32.16%
IN:SHREEPUSHK
Shree Pushkar Chemicals & Fertilisers Ltd.
288.90
5.36
1.89%
IN:SRHHYPOLTD
Sree Rayalaseema Hi-Strength Hypo Limited
423.70
-91.20
-17.71%
Uniphos Enterprises Limited Corporate Events
Uniphos Enterprises Closes Trading Window Ahead of Unaudited Results
Dec 31, 2025
Uniphos Enterprises Limited has announced that its trading window for company insiders will be closed from 1 January 2026 in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code on handling unpubl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.